Table 1 Inclusion and exclusion criteria for clinical DDI abstract selection

Inclusion (positive)

Clinical trial DDI study: Phase I/II/III clinical trials in which drug combination and/or single drug ADE are evaluated and reported.

Pharmaco-epidemiological DDI study: Pharmaco-epidemiology studies in which ADEs from drug combinations are reported and compared to single drug ADEs.

DDI and ADE case reports: DDI-induced ADE cases in which the time sequential drug and ADE are reported in clinical care settings.

Exclusion (negative)

Clinical PK DDI study: both single drug and drug combination exposures (i.e. pharmacokinetics) are evaluated either in patients or healthy volunteers.

Clinical PK PG study: the single drug exposure (i.e. pharmacokinetics) is evaluated among patients that have different genotypes in CYP450 and UGT enzymes and drug transporters.

in vitro PK study: substrate depletion and metabolite formation study is for the fm data collection; and inhibition study is for the Ki data collection.

Drug interaction detection algorithms or software

Compliance of avoiding DDI

Concordance of DDI reporting among different drug interaction knowledge base.

Comparison of the performance of DDI clinical decision systems

Drug-alcohol/food interactions

Drug/test interactions

Case report studies

Review papers

Cell culture and animal studies

Other studies that are not related to drug interactions.